Introduction
, although this mutant probably The Mos proto-oncogene protein kinase activates the does not possess cytostatic factor (CSF) activity MAP kinase cascade in vertebrate oocytes by phospho- (Nishizawa et al., 1992) . However, the S3A mutant rylation of the MAP kinase-activating kinase MEK. exhibits reduced interaction with its substrate MEK and Mos function controls MAP kinase activation during a does not activate endogenous MAP kinases when short window of development, the meiotic maturation expressed in reticulocyte lysates (Chen and Cooper, 1995) , of oocytes. MAP kinase activation is required for efficient unlike wild-type Mos. Furthermore, in mammalian v-Mos, Cdc2 activation during Xenopus oocyte maturation (for mutation of the equivalent residue Ser34 to alanine inhibits a review, see Sagata, 1997; Ferrell, 1999; Fisher et al., v-Mos activity (Yang et al., 1998) . Mos has recently been 1999a), which represses DNA replication between shown to interact with the chaperone Hsp70, an interaction meiosis I and meiosis II (Furuno et al., 1994; Picard that probably requires Ser3 (Liu et al., 1999) . The role of et al., 1996) , and to maintain a stable metaphase arrest this interaction in Mos regulation is not clear. necessary for fertilization (Haccard et al., 1993; Colledge We have recently demonstrated that interference with the et al., 1994; Hashimoto et al., 1994) . Mos is inactivated function of Hsp90 prevents activation of MAP kinase in after exit from meiosis (Lorca et al., 1991; Xenopus oocyte maturation (Fisher et al., 1999a (Fisher et al., ), but how et al., 1991 Roy et al., 1996) and this inactivation is prevention of MAP kinase activation is mediated was not required to allow entry into first mitosis (Abrieu et al., analysed. Here we show that Mos interacts with Hsp90 in 1997; Walter et al., 1997; Bitangcol et al., 1998; the oocyte and that this interaction is necessary for Mos et al., 1998) or, possibly, the first round of DNA activation, and thus for Mos-mediated MAP kinase activareplication in some species (Tachibana et al., 1997) .
tion. This defines for the first time an activation step in The activation and inactivation of Mos thus control the the regulation of Mos. We also demonstrate a biphasic cell cycle at a crucial period of development. To ensure activation of MAP kinase in progesterone-stimulated the correct timing, Mos is regulated at several levels, including mRNA polyadenylation and translation oocytes.
Results

Mos can be translated but is underphosphorylated and does not activate the MAP kinase cascade if Hsp90 is inhibited
We have recently reported that the specific Hsp90 inhibitor geldanamycin (GA) blocks sustained activation of MAP kinase in Xenopus oocytes (Fisher et al., 1999a) , although we did not define the molecular target of Hsp90 inhibition. Mos translation is part of a positive feedback loop in which MAP kinase stimulates, and is apparently required for, Mos synthesis (Matten et al., 1996; Howard et al., 1999) . Since Mos is required for MAP kinase activation in Xenopus and mouse oocytes, we hypothesized that the target for Hsp90 inhibition may be Mos synthesis.
We therefore analysed the time course and dependence on Hsp90 function of Mos accumulation. Mos normally only accumulates to low levels before GVBD and undergoes a dramatic increase in accumulation at GVBD, along with a shift in mobility ( Figure 1A , lanes 1-5). To allow initiation events potentially dependent on Hsp90, in this experiment GA was added after 20 min of progesterone treatment. In the absence of subsequent Hsp90 function, Mos can still attain approximately the same level, but MAP inhibitor just before, at the same time as or just after cyclin B protein (cycB) was microinjected into either untreated (-) oocytes or oocytes pre-treated (for 2 h) and maintained in GA (ϩGA) progesterone addition, and examined Mos accumulation to compare induction of Mos translation and phosphorylation, and and mobility, as well as the ability of GA to maintain dependence on Hsp90 function, with control stage VI (S) and MAP kinase inactive, 6 h later ( Figure 1C ). We did not progesterone-matured (P) oocytes. All cyclin B-injected oocytes detect any differences due to the timing of GA addition, underwent GVBD and were homogenized in buffer A and analysed as above.
suggesting that Mos is first synthesized in an unphosphorylated state, that this does not require Hsp90 and that there is a reasonable time window in which Hsp90 but not the Ala3 mutant was phosphorylated rapidly and inhibition prevents subsequent phosphorylation of Mos.
electrophoretically retarded on injection into mature but We reasoned that induction of Cdc2 kinase, other than not stage VI oocytes (data not shown). The missing by progesterone, should also lead to phosphorylation of phosphorylation on Mos synthesized in the presence of Mos in an Hsp90-dependent fashion. We have previously GA is thus probably either Ser3 or a site or sites dependent reported that MAP kinase is not activated on microinjection on prior Ser3 phosphorylation. These results suggest that of glutathione S-transferase (GST)-cyclin B in the presphosphorylation of Mos on Ser3 is a step in Mos activation, ence of GA (Fisher et al., 1999a) . In this experiment and that Hsp90-dependent Mos phosphorylation is required ( Figure 1D ), cyclin B injection, like progesterone treatfor Mos activation. ment, provoked accumulation and mobility shift of Mos, These results also suggested that Mos activation, rather but pre-treatment with GA prevented the mobility shift.
than accumulation, may be inhibited by blocking Hsp90, This confirms the dependence of Mos phosphorylation on a result consistent with our report that recombinant Mos Hsp90 function.
protein does not activate MAP kinase on microinjection Mobility shift of Mos has previously been demonstrated into oocytes in the presence of GA (Fisher et al., 1999a) . to be abolished by the mutation Ser3Ala (Nishizawa Nevertheless, we wished to eliminate the possibility that et al., 1992), and we confirmed by injection of in vitro GA has general effects on protein synthesis. We therefore examined the ability of GA-treated oocytes to incorporate synthesized 35 S-labelled proteins that indeed the wild type Oocytes were treated with GA as in upper panel), homogenized after 3 h when nonmicroinjected with~25 ng of capped mRNA for GST-Mos, either wild GA-treated samples had undergone GVBD, and analysed by Western type (wt) or kinase-dead (kd) mutant versions; oocytes were incubated blotting for active MAP kinase. (B) Control oocytes (ct) or oocytes overnight and homogenized in buffer A. GST pull-downs (GSTpd) were injected with capped mRNA (~25 ng) for kinase-dead GST-Mos, either performed as described in Materials and methods, and total extracts or pre-treated and maintained in GA (ϩGA) or subsequently treated with GST pull-downs were run on SDS-PAGE and Western blotted with progesterone (ϩP), were homogenized after 6 h expression, and two either anti-Mos, anti-Hsp70 or anti-Hsp90 antibodies as indicated. oocytes/lane were analysed by Western blotting for Mos expression.
(A) Lanes 1-4, total homogenates; lanes 5-8, GST pull-downs. S, (C) A similar experiment to that in (B) except that the mRNA injected stage VI oocytes; P, progesterone-treated mature oocytes; Mos, oocytes (~5 ng/oocyte) encoded GSK-3β, and two time points were taken at 6 injected with wild-type GST-Mos mRNA; two oocytes/lane; GSTpd, and 22 h after mRNA injection.
GST pull-downs, the equivalent of 10 oocytes/lane; ct, control GST pulldown from progesterone-treated but non-injected mature oocytes. (B) A similar experiment to that in (A) using kinase-dead GST-Mos mRNA methionine. One hour later, oocytes were lysed in Laemmli buffer, run on SDS-PAGE and incorporated label was analysed by autoradiography. GA treatment had no effect exists it is either labile, transient or of low abundance. Nevertheless, our results show that inhibition of Hsp90 on this basal protein synthesis, although in the same batch of oocytes treated at the same time GA still inhibited interferes with Mos function. We therefore re-examined the possibility that Mos may associate with Hsp90 in vivo. progesterone-induced MAP kinase activation ( Figure 2A , lower panel). Secondly, we analysed the ability of GAWe took advantage of a new system to detect proteinprotein interations in Xenopus by GST pull-down of treated oocytes to translate mRNA. Again oocytes were pre-treated and maintained in GA (ϩGA) or not (-), in vivo synthesized proteins (MacNicol et al., 1997) . Mos expressed in this way indeed interacted with Hsp70, and injected with RNA encoding kinase-dead GST-Mos, which does not induce GVBD, left to express for 6 h, and we also found that Hsp90 is present in the Mos complexes ( Figure 3A ), although its presence is hard to detect. The lysed and analysed by Western blot. GA had no effect on translation of injected mRNA ( Figure 2B ). We confirmed Mos-Hsp90-Hsp70 complex did not depend on kinase activity of Mos since the kinase-dead version interacted that this was a general phenomenon by analysing expression of mRNA for an unrelated kinase, GSK-3β, in the to the same extent. Hsp90 was no longer present in the complex when oocytes were treated with GA, but Hsp70 absence and presence of GA ( Figure 2C ), and a nondegradable version of the transcription factor β-catenin was not only still present, but it actually interacted to a greater extent when interaction with Hsp90 was blocked (data not shown). Thus, GA treatment does not affect general protein synthesis. In contrast, stimulation of ( Figure 3A ). This suggests that Mos interacts sequentially with Hsp70 and Hsp90 during its activation, that interinjected oocytes to mature with progesterone did cause an increase in translation of injected mRNA in the same action with Hsp90 may well be transient and that interaction with Hsp90 leads to reduced binding of Hsp70. period of time ( Figure 2B , ϩP), which was also a general effect (data not shown).
The S3E mutation, which mimics phosphorylation of Mos Ser3, did not increase the level of complexed Hsp90 over that of the kinase-dead version, and this interaction was
Mos interacts with Hsp90 as well as Hsp70 in the oocyte also abolished in the presence of GA (data not shown).
To try and find independent evidence for an inverse A recent report has found that Mos interacts with Hsp70 in Xenopus oocytes, although the function of this interrelationship between the association of Mos with Hsp70 and with Hsp90, we expressed kinase-dead Mos (to avoid action is not clear and interaction with Hsp90 was not seen (Liu et al., 1999) , implying that if such an interaction possible confusion due to events potentially due to the 
Mos is not activated without functional Hsp90
The above results demonstrate that Mos-induced activation Moreover, MAP kinase activation has been reported to (-) during expression in 5 μM GA (GA), were homogenized and require both Mos kinase (Roy et al., 1996) basis of in vitro experiments (Huang and Ferrell, 1996) . To examine whether MAP kinase itself could require Hsp90 function in order to be activated, we sought to activity of Mos) in oocytes and lysed them after overnight activate a MAP kinase-activating pathway that does not expression either in the presence of EDTA, to chelate require Mos. In Xenopus oocytes, oncogenic ras-induced magnesium and therefore potentially reduce Hsp90 func-GVBD does not require Mos synthesis (Daar et al., 1991) tion, or in the presence of high concentrations of ATP and nor, apparently, any other protein synthesis (Allende et al., magnesium (10 and 20 mM, respectively) , potentially to 1988; Nebreda et al., 1993) . We therefore examined stabilize an interaction with Hsp90. Although EDTA does whether oncogenic ras-mediated activation of MAP kinase not inhibit Hsp90 association, ATP/Mg does promote requires Hsp90 function, by injecting recombinant this interaction, and when the interaction with Hsp90 is Ras-Lys12, a constitutively active form of ras, in the stabilized a reduced interaction with Hsp70 is seen, to absence and presence of GA. If Mos is indeed a target of only just above background levels ( Figure 3B ). As before, Hsp90 inhibition, we might expect that Ras-Lys12 may if we inhibit Hsp90 function with GA, it no longer interacts activate MAP kinase in the absence of Hsp90 function. with Mos, although Hsp70 can still interact ( Figure 3B ).
This was indeed the case: ras-Lys12 protein injection induced GVBD and MAPK activation ( Figure 5 ) whether or not GA, which as usual inhibited progesterone-induced Mos-E3 still requires Hsp90 function to induce MAPK activation and GVBD MAPK activation, was present. This demonstrates that Hsp90 function is not essential for activation of MAP Since phosphorylation of Mos and the activation of MAPK by Mos are inhibited by interfering with Hsp90, and some kinase per se, and reinforces the idea that Hsp90 inhibition specifically targets Mos. reports suggest that phosphorylation of Mos Ser3 may be required for full activity, we wondered whether Mos activaThese results point to a requirement for Hsp90 in progesterone-stimulated activation of MEK by Mos. We tion might be due solely to this phosphorylation step. If so, the mutant S3E should no longer require functional Hsp90 tested this hypothesis directly by measuring MEK activity using recombinant GST-MAP kinase as a substrate, either to induce activation of MAP kinase. This was not the case (Figure 4) . Even though Mos-E3 was as highly overexin total lysates ( Figure 6A , first four lanes) or on immunoprecipitation of endogenous MEK from the lysates pressed as the wild type (Mos-WT), neither could induce GVBD (associated with Cdc25 hyperphosphorylation) nor ( Figure 6A , right-hand five lanes). MEK was inactive in stage VI oocytes (S), active in progesterone-treated mature activate MAP kinase in the presence of GA, although both were equally efficient in normal circumstances. Because, in oocytes (P), but not if treated with GA during the window in which Mos phosphorylation can be prevented (P ϩ GA). the presence of GA, expression of the two Mos proteins could not induce GVBD and the associated increase in Thus, the underphosphorylated Mos that accumulates ( Figure 6B ) is incapable of activating MEK in the absence protein translation that occurs on oocyte maturation, Mos did not accumulate to the same extent as in non-treated of Hsp90 function. Since MAP kinase can phosphorylate Mos on Ser3, we samples. GA does not in itself inhibit the expression of these mRNAs ( Figure 2B and data not shown).
wished to determine whether the lack of activation of MEK is indirect, due to a lack of MAP kinase, or whether GA These results imply that an Hsp90-dependent event subsequent to Mos-S3 phosphorylation is important for has a direct effect on Mos kinase. To achieve this, we overexpressed the MAP kinase phosphatase Pyst1, which Mos activation. , progesterone-treated mature oocytes (P) or oocytes treated with progesterone to which 5 μM GA was added after 1 h (P ϩ GA) were homogenized in buffer A and frozen in liquid nitrogen. (A) An aliquot of each sample (equivalent to one oocyte) was incubated in a total MEK kinase assay using recombinant Fig. 8 . In vivo translated Mos requires Hsp90 function for expression GST-MAP kinase as described in Materials and methods (-, the of its kinase activity. (A) Preparatory experiment in which total control kinase assay in the absence of oocyte extract demonstrates that stage VI (S) or progesterone-matured (P) oocyte extracts (one oocyte/ the low intensity band is due to background autophosphorylation or lane) were incubated in a kinase assay using kinase-dead GST-MEK fixation of ATP by the substrate GST-MAP kinase), while most of the as described in Materials and methods. (-) and (ϩ) indicate the remainder of each sample (equivalent to 20 oocytes) was used to absence or presence of kinase-dead GST-MEK substrate or (lane 1 immunoprecipitate MEK, with either a pre-immune (Pr) or immune only) extract. (B) The experiment was then repeated (lower three (Im) serum, and the washed pellet was used in a MEK kinase assay panels) with stage VI (S), progesterone-matured (P) or progesterone using recombinant GST-MAP kinase. Kinase assays were stopped by and GA-treated (5 μM, 1 h after progesterone) oocytes. An aliquot of heating in Laemmli buffer, resolved on SDS-PAGE and the dried gel the total extract was Western blotted for Cdc25 and Mos (lower two was autoradiographed to reveal phosphorylated GST-MAP kinase. panels). (C) Capped mRNA for wild-type (wt) or kinase-dead (kd) (B) Another aliquot of each sample was resuspended in Laemmli GST-Mos was injected into oocytes (25 ng/oocyte), a subset of which buffer for total Western blots using the antibodies indicated.
were incubated in 5 μM GA (wt ϩ GA), and oocytes were incubated overnight and homogenized in buffer A. In vivo translated Mos was recovered from the extracts by pull-down from 100 μl of extract on glutathione-Sepharose beads (GSTpd) and either run on SDS-PAGE and Western blotted to estimate recovery (middle panel, equivalent of 10 oocytes/lane) or incubated in a Mos kinase assay (lower panel, equivalent of 10 oocytes/assay) followed by resolution and autoradiography on SDS-PAGE. The upper panel shows Western blots of total oocyte extracts (three oocytes per lane) from this experiment, as well as control stage VI (S) and progesterone-treated (P) oocytes not overexpressing GST-Mos, in which synthesized endogenous Mos is indicated. Slightly less Mos protein is synthesized in GA-treated or kinase-dead Mos-injected oocytes since they did not undergo GVBD, which enhances general protein translation. (D) A similar experiment to that in (B) was performed using mRNA for wild-type (wt) and S3E Fig. 7 . Active MAP kinase is not required for MEK activation by Mos-GST; ct, GST pull-down from progesterone-matured oocytes not newly translated Mos. Stage VI (S), progesterone-matured (P) and injected with Mos mRNA. progesterone-treated oocytes pre-injected with~10 ng of capped mRNA for Pyst1 and incubated overnight before progesterone treatment were subjected to total Western blots for Mos and active MAP kinase, and MEK immunoprecipitation kinase assays as precipitation from Xenopus oocytes is notoriously difficult described in Figure 6. (e.g. see Liu et al., 1999) . It is theoretically possible that underphosphorylated Mos could phosphorylate MEK without activating its kinase activity. We therefore assayed blocks MAP kinase activation in Xenopus oocytes (Fisher et al., 1999a) . No MAP kinase activity could be detected, total kinase activity against kinase-dead GST-MEK in extracts of Xenopus oocytes in normal circumstances or but Mos accumulates (albeit to a lower level in oocytes that do not undergo GVBD, due to the suppression of MAP circumstances in which Mos is underphosphorylated and may be inactive. The results exclude the possibility that kinase activity) and migrates at the same mobility as fully active Mos, and MEK is activated (Figure 7 ). This suggests, Mos phosphorylates MEK without activating it: control progesterone-treated oocytes contained abundant activity but still does not prove directly, that Mos enzymatic activity is targeted directly by inhibition of Hsp90.
able to phosphorylate MEK ( Figure 8A and B, upper panel), while treatment of oocytes with GA abolished this Measurement of Mos kinase activity by immuno-activity, and accumulated Mos remained in its underphosphorylated form ( Figure 8B, upper and lower panels) . In these oocytes, GA suppressed hyperphosphorylation of Cdc25 and GVBD ( Figure 8B, middle panel) .
To test further whether activation of in vivo translated Mos requires Hsp90 function, we overexpressed GSTMos in vivo and assayed its intrinsic kinase activity by autophosphorylation of GST pull-downs. We overexpressed either GST-Xenopus Mos wild-type (WT), S3E or kinase-dead (KD) proteins by injection of the corresponding mRNAs. Only GST-Mos-WT and Mos-E3 in the absence of GA activated the MAP kinase cascade, caused GVBD and possessed intrinsic autophosphorylation activity ( Figure 8C and D) , even though in the presence of GA the Mos proteins were expressed at a much higher level ( Figure 8C , upper panel) than the endogenous Mos, which accumulates on progesterone-induced maturation. This directly demonstrates that GST-Mos requires Hsp90 inactivation of MAP kinase and exit from a CSF extract (data not shown). Thirdly, on progesterone stimulation, there is a time window in which GA addition inhibits Mos and MAP kinase activation, but after which Mos and MAP kinase go on to be phosphorylated and activated in spite of the presence of GA (data not shown). Also, as shown in Figure 9A , incubation of oocytes arrested in meiosis II in GA does not lead to dephosphorylation and inactivation of Mos and MAP kinase. Thus, GA inhibits only the step in which Mos activation occurs, and cannot inactivate Mos that has already passed this step. To analyse directly whether Hsp90 is still required for kinase activity once Mos has already been activated, we analysed kinase activity of GST-Mos expressed in oocytes by GST pull-down kinase assays ( Figure 9B ). In this experiment, GA was either absent, present in the oocyte medium before (B) expression to block activation of Mos or present afterwards (A) during the GST pull- 
oocytes
The above results show that Mos is inactive in the absence of an Hsp90-dependent event, coincident with phorylation is detectable as early as 15 min after progesterone addition, in advance of a detectable increase in Mos Mos phosphorylation. However, we have recently reported that MAP kinase is activated to a low level early in protein level. Secondly, surprisingly, there is apparently an early peak in MAP kinase phosphorylation, at 30 min response to progesterone. This infers that activation of MAP kinase may be a coordinate response to Mosin this experiment, before a later large-scale increase. This is not an artefact of inaccurate gel loading since β-tubulin dependent and -independent activation steps. To define the activation curve of MAP kinase more precisely, we is constant throughout (lower panel). An alternative explanation, which we cannot yet rule out, is that there performed a detailed time course, as shown in Figure 10A . This shows first that an increase in MAP kinase phosare two MAP kinases in which the active form migrates at the same size, and one is activated early while the other c-Mos, possibly by activation of MAP kinase to a low but sufficient level to stimulate endogenous Mos translation, is activated later.
We then tested the requirement for protein synthesis in and/or by titration of an inhibitor. Putative inhibitors of c-Mos include the β-subunit of casein kinase II, which, when early activation of MAP kinase. Figure 10B demonstrates that 20 μg/ml cycloheximide treatment prior to and during ectopically expressed, has been shown to inhibit c-Mos activation and meiotic maturation, and a complex between the progesterone time course abolishes both phases of MAP kinase activation; thus, even if the early peak of this protein and endogenous c-Mos has been detected (Chen et al., 1997) . Ser3 has been reported to be important for the MAP kinase is independent of Mos, it requires synthesis of an as yet unidentified protein.
interaction with Hsp70 (Liu et al., 1999) , although we show here that binding of Hsp70, while not impaired by GA, is not sufficient to allow Ser3 phosphorylation and c-Mos
Although Ser3 phosphorylation is almost certainly It has been known for some time that Mos activates the MAP kinase cascade during meiosis in vertebrate oocytes required for c-Mos activity, Hsp90 function is not only required for this event. S3E, which, in contrast to S3A, and it has recently become clear that Mos-mediated control of MAP kinase is critical for the correct ordering and timing readily induces cleavage arrest when microinjected into the blastomere of a two-cell embryo (Nishizawa et al., 1992) , of events at the beginning of development, including suppression of DNA replication in meiosis and prevention of still requires Hsp90 function for expression of its protein kinase activity. Mos possesses an autoinhibitory loop, near parthenogenetic activation (see Sagata, 1997) . Nevertheless, the mechanism of activation of Mos itself has not the active site, which must be repositioned in order to allow expression of the kinase activity (Robertson and Donoghue, been determined. Here we describe a system that allows investigation of the mechanism of activation of the Mos 1996) . Interaction with Hsp90 may well mediate the repositioning of this region. It is also possible that subsequent protein kinase by uncoupling its synthesis and activation.
Although a recent report has demonstrated an interaction phosphorylation could stabilize this conformation change, eliminating a further requirement for Hsp90 in maintenance between Mos and Hsp70, the functional significance of this interaction is unknown (Liu et al., 1999) . We demonstrate of Mos activity.
Translation of c-Mos in progesterone-stimulated oocytes here that Mos interacts with another chaperone, Hsp90, and that this interaction is essential for its activation. Furtherrequires unmasking and polyadenylation of stored mRNA (Sheets et al., 1995) . A surprising aspect of this translational more, we show an inverse relationship between the association of Mos with Hsp90 and its association with control is that it apparently requires MAP kinase activation (Howard et al., 1999) even though MAP kinase activation Hsp70.
Hsp90 has recently been described as a cofactor for is supposedly downstream of Mos. We nevertheless show that Mos accumulation does not require Hsp90 activity and several protein kinases, including casein kinase II, the cell cycle kinases Wee1 and Cdk4, and the proto-oncogenes occurs even if we can no longer detect MAP kinase activity. Although we have been unable to provide supporting Raf-1 and Src, as well as a modulator for a variety of other proteins including the heat-shock transcription factor evidence, it is possible that the early low level of MAP kinase activation after progesterone stimulation (Fisher HSF1, the steroid receptors for glucocorticoid and progesterone, and the centrosomal protein centrin (for a review, et al., 1999a) could be due to Raf-1. Hsp90 could also be required for Raf-1 function, as is the case in mammalian see Caplan, 1999) . Hsp90 is inhibited efficiently by the anti-tumour agent GA, which binds to a region involved cells, as well as Mos, and Raf-1 might be activated early while Mos is activated later. Indeed, we have shown that in ATP binding. This agent is extremely potent in prevention of activation of MAP kinase in Xenopus oocytes if Hsp90 is inhibited at the same time as progesterone stimulation, no MAPK activation is observed (Fisher et al., (Fisher et al., 1999a) , and we show here that this inhibition can be explained by an inhibition of the mechanism that 1999a; this study). Another possibility is that B-raf, rather than Raf-1, is responsible, since a ras-dependent activator activates Mos kinase.
We find that prevention of Mos association with Hsp90 of MAP kinase from Xenopus eggs has been purified and identified as B-raf Yamamori et al. , by GA abolishes not only its kinase activity but also its phosphorylation-induced SDS-PAGE mobility shift, due to 1995). A model could place Raf-1 or B-raf at the cortex where it would be activated early after the binding of Ser3 phosphorylation (Nishizawa et al., 1992) . This correlation suggests that Ser3 phosphorylation may be required for progesterone to its receptor. This would permit the early low level of MAP kinase activation. c-Mos activation in Xenopus oocytes, and indeed the S3A mutant does not interact efficiently with MEK in vitro, Newly synthesized non-phosphorylated Mos is degraded (Watanabe et al., 1989; Nishizawa et al., 1992) , while and fails to activate endogenous ERK1 and ERK2 when expressed in reticulocyte lysates, in contrast to wild-type association with Hsp70 may stabilize the protein (Liu et al., 1999) , perhaps by preventing its proteolysis. Binding c-Mos (Chen et al., 1995) . The view that Ser3 phosphorylation is required for c-Mos activity has been challenged of Hsp90 probably occurs after that of Hsp70, since GA does not prevent (and may increase) Hsp70 binding while because S3A mutants readily induce GVBD when microinjected into G 2 -arrested oocytes (Freeman et al., 1992;  ATP promotes Hsp70 dissociation and Hsp90 binding. Binding of Hsp90 fulfils two roles in the process of c-Mos Nishizawa et al., 1992) , although protein kinase activity of this mutant was not documented directly in these experiactivation. One is to allow Ser3 phosphorylation. Several Ser3 kinases have been proposed, including MAP kinase ments. Mos S3A possesses either no, or very low kinase activity (Yang et al., 1998) , and it is likely that microinjecand Cdc2-cyclin B, for which Mos Ser3 fulfils consensus site requirements. We demonstrate here that MAP kinase tion of S3A leads to translation and activation of endogenous dead genes were cloned into the Xenopus expression vector pXen1 (MacNicol et al., 1997) to allow production of GST-tagged Mos mRNA by SP6 in vitro transcription. Capped mRNAs were transcribed by standard procedures (Promega).
Xenopus oocytes
Oocyte manipulations, in MMR (5 mM HEPES pH 7.8, 1.1 M NaCl, 2 mM KCl, 0.1 mM EDTA, 1 mM MgCl 2 , 2 mM CaCl 2 ), and extracts in buffer A [20 mM Tris pH 7.5, 50 mM NaCl, 50 mM NaF, 10 mM β-glycerophosphate, 5 mM Na 4 P 2 O 7 , 1 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine] were performed as described (Fisher et al., 1999b) . GA was dissolved in dimethylsulfoxide (DMSO) at a concentration of 5 μmol/ml and diluted in MMR to the concentration indicated (usually 5 μM).
Immunological procedures
The Xenopus anti-Mos, anti-ERK and anti-active ERK antibodies were obtained from Santa Cruz (sc-086, sc-94 and sc-7383, respectively). Other antibodies used were rabbit polyclonal antisera against Xenopus full-length recombinant Cdc25, anti-Xenopus MEK C-terminal peptide, the polyclonal anti-pleurodeles Hsp90 antibody kindly provided by Patrick Coumailleau (Coumailleau et al., 1995) , and monoclonal anti- 1995), both kindly provided by David Toft. Immunoprecipitations for kinase assays were performed as described (Fisher et al., 1999b Cdc2 antibodies prevent activation of at least the majority of 150 mM NaCl and assayed for 30 min at 25°C in 25 μl of reaction buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 15 mM MnCl 2 , 2 mM MAP kinase activation (Nebreda et al., 1995) . is required for high-level Cdc2 activation in Xenopus oocytes (Fisher et al., 1999a) . This, along with a two-phase
Antisense Mos oligonucleotides
Antisense oligonucleotides were based on those already tested in Xenopus MAP kinase activation (early low level, late high level oocytes (Sagata et al., 1988) , in this case CATATCCTTGCTTGTATTdue to Mos activation) provides a conceptual basis for the TTCAGTGC. Oligonucleotides were dissolved in water at 2 μg/μl, and feedback loop of MAP kinase and Cdc2 activation 50 nl were microinjected into stage VI oocytes, which were left for ( Figure 11 ). The missing link is the step at which MAP 30 min before progesterone treatment.
kinase promotes Cdc2 activation; on the basis of other reports (Ballantyne et al., 1997) , we have suggested that the
